Method for treating pulmonary arterial hypertension in combination with lalymph and other drugs

摘要

The disclosure includes a combination of a laGlyg and a cGMP concentration-enhancing agent or prostanoid, such as riociguat, treprostinil, or iloprost, for treating PAH. The disclosed combination therapies may improve efficacy, improve safety, reduce the dose and / or frequency of lalymph and / or riociguato, reduce the dose and / or frequency of lalymph and / or treprostinil, or lalygue and / or Benefits include a reduction in iloprost dose and / or frequency. In some embodiments, the clinical efficacy of the reduced dose combination is additive or synergistic compared to that provided by the corresponding monotherapy of lalymph, riociguat, treprostinil, and / or iloprost. [Selection] Figure 12